4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Current Assets data on file, last reported at $405.4 million in Q1 2026.

• On a quarterly basis, Current Assets rose 21.89% year-over-year to $405.4 million in Q1 2026; TTM through Mar 2026 was $405.4 million, a 21.89% increase from a year earlier, with the FY2025 full-year figure at $413.1 million, down 5.01% from the prior year.
• Current Assets for Q1 2026 stood at $405.4 million, down from $413.1 million in the prior quarter.
• Over the last five years, Current Assets for FDMT reached as high as $552.6 million in Q2 2024 and fell as low as $207.0 million in Q1 2023.
• Historically, Current Assets has averaged $346.6 million across 5 years, with a median of $317.8 million in 2023.
• Across the five-year window, Current Assets soared 158.69% in 2024 and tumbled 45.12% in 2025, its largest moves.
• Year by year, Current Assets stood at $220.5 million in 2022, then soared by 34.5% to $296.6 million in 2023, then soared by 46.65% to $434.9 million in 2024, then slipped by 5.01% to $413.1 million in 2025, then dropped by 1.88% to $405.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $405.4 million in Q1 2026, $413.1 million in Q4 2025, and $312.4 million in Q3 2025.